The Board of Directors of SalusAnsvar recommends the public offer by DnB NOR for the shares of SalusAnsvar

The Board of Directors of SalusAnsvar recommends the public offer by DnB NOR for
the shares of SalusAnsvar

This press release is not and must not, directly or indirectly, be distributed
or made public in USA, Australia, Canada, Japan or South Africa. The Offer is
not being made to persons in those jurisdictions or elsewhere where their
participation requires further offer documents, filings or other measures in
addition to those required by Swedish law.
This press release has been published in Swedish and English. In the event of
any discrepancy between the Swedish and the English version, the Swedish version
shall prevail.
Background 
This statement is issued by the Board of Directors of SalusAnsvar AB (publ)
("SalusAnsvar") pursuant to Item II.14 of the Stockholm Stock Exchange Rules
concerning Public Offers for the Acquisition of Shares.
The Offer
The Norwegian bank DnB NOR Bank ASA ("DnB NOR") has today announced a public
offer to the shareholders of SalusAnsvar to acquire all outstanding shares in
SalusAnsvar (the “Offer”). According to the Offer, SalusAnsvar's shareholders
are being offered to tender their shares for a consideration of SEK 35 per
series A share and SEK 35 per series B share in SalusAnsvar. 

Compared to SalusAnsvar's average trading share price per series B share on the
Stockholm Stock Exchange for the last thirty trading days, the Offer represents
a premium of 48 percent. Compared to the share price per series B share on the
Stockholm Stock Exchange on 17 August 2007, the last trading day before the
announcement of the Offer, the premium was 57 percent. The series A share is
unlisted.  

Sveriges läkarförbund, Praktikerinvest AB and Roppongi, ömsesidig sakförsäkring,
in liquidation, which at the time of the announcement of the Offer represented
approximate 51 percent of the votes of SalusAnsvar, have, towards DnB NOR,
committed, under certain conditions, to accept the Offer.

The Offer is, among other conditions, conditional upon being accepted to such an
extent that DnB NOR becomes the owner of more than 90 percent of the total
number of shares in SalusAnsvar. The acceptance period is expected to commence
on 17 September 2007 until 12 October 2007. The settlement report for the Offer
is expected approximate one week after the end of the acceptance period and the
conditions for the Offer have been fulfilled or released. 

The Board of Directors of SalusAnsvar has allowed a limited so called due
diligence prior to the announcement of the Offer. 

SalusAnsvar's Board of Directors has in connection to the Offer received
financial advice from Handelsbanken Capital Markets and legal advice from
Setterwalls Advokatbyrå. Handelsbanken Capital Markets has rendered a so called
fairness opinion to the Board of Directors of SalusAnsvar concerning if the
Offer is fair. Handelsbanken Capital Markets has in the above mentioned fairness
opinion stated that the renumeration in the Offer is fair from a financial point
of view to the shareholders in SalusAnsvar.

The recommendation by the board of directors
The Board of Directors has before its statement considered factors that the
Board of Directors has deemed relevant in relation to the Offer, including,
inter alia SalusAnsvar's financial position and future prospects with therewith
related possibilities and risks as well as the fairness opinion which the Board
of Directors has obtained from Handelsbanken Capital Markets, regarding the
fairness of the Offer for the shareholders' in SalusAnsvar, including, inter
alia, the difference between the Offer price and SalusAnsvars' listed share
price. It is the Board of Directors' opinion that DnB NOR from an industrial
point of view is a good purchaser for the customers, development of the company
as well as for its personnel. 

Based on the above, it is the Board of Directors' assessment that the Offer is
fair and the Board of Directors unanimously recommends SalusAnsvar's
shareholders to accept the Offer.
The Director, Catarina Andersson Forsman, Chief Executive Officer of Sveriges
läkarförbund, and the Director Gillis Cullin, Chief Executive Officer in
Praktikerinvest AB, have not participated in the Board of Directors' decision
regarding the Offer due to the made commitments to accept the Offer. 

This statement shall in all respects be governed by and construed in accordance
with Swedish law. Any dispute arising out of or in connection with this
statement shall be settled exclusively by Swedish courts.
Stockholm August 20, 2007
SalusAnsvar AB (publ)
The Board of Directors 


For further information contact:
Bo Ingemarson, Chairman of the Board +46 (0)703 49 45 77
Carl-Viggo Östlund, Chief Executive Officer +46 (0)8 55 54 50 01, +46 (0)709 11
60 01

SalusAnsvar AB (publ) is on the Small Cap list of the OMX Nordic Exchange
Stockholm. SalusAnsvar's mission is to boost the competitiveness of
organisations by offering insurance and banking services that generate added
value for its members. 
SalusAnsvar's primary customers are organisations and end-customers who are
members of these 
organisations. The market comprises some 1.9 million people consisting of
members and their families in some of the 60 organisations with which
SalusAnsvar collaborates. SalusAnsvar has some 540,000 customers.